BioSpace News Archive

Business

Anticipating FDA Yes, Provention Inks Co-Promotion Deal with Sanofi for T1D Drug

Provention Bio entered a co-promotion agreement with Sanofi ahead of the possible November approval of teplizumab. If approved, the drug would be the first approved to modify T1D.

October 6, 2022
·
3 min read
·
Mark Terry
Business

Movers & Shakers: New C-Suites for Assembly Biosciences, Urica Therapeutics, BlueSphere Bio and More

Life sciences and biopharma companies added new CEOs, CMOs and CSOs to guide their companies into the future and oversee developmental programs.

October 6, 2022
·
4 min read
·
Alex Keown
Drug Development

Clinical Catch-Up: Adocia, Allecra and Aldeyra

Adocia, Allecra Therapeutics and Aldeyra Therapeutics announced promising results in Type I Diabetes, urinary tract infections and retinal diseases.

October 6, 2022
·
3 min read
·
Vanessa Doctor, RN
Business

Biotech Bay’s Newest VC Source: Red Tree Capital Closes $272M Inaugural Fund (Updated)

Red Tree Venture Capital closed a $272 million inaugural fund that will be used to support the development of therapeutics addressing unmet needs in oncology, neurology and immunology.

October 6, 2022
·
3 min read
·
Alex Keown
Business

Boehringer and Surrozen Seek Retinal Therapies Along the Wnt Pathway

Surrozen announced Thursday it has partnered with Boehringer Ingelheim to research and develop a therapeutic for the treatment of retinal diseases.

October 6, 2022
·
3 min read
·
Alex Keown
Drug Development

Battered by Setbacks, Eliem is Back on Track in MDD

After an earlier stumble this year with its investigational major depressive disorder therapeutic, Eliem Therapeutics appears to be back on track with a planned Phase II study of ETX-155.

October 6, 2022
·
3 min read
·
Alex Keown
Drug Development

Lilly’s Mounjaro is on the Fast Track Toward Potential Obesity Approval

Eli Lilly gained ground in the obesity market Thursday as the FDA granted Fast Track designation to Mounjaro (tirzepatide), an investigational drug for adults with obesity.

October 6, 2022
·
2 min read
·
Mark Terry
Drug Development

Experts Extol Combination Therapies as Future of Alzheimer’s Treatment

While Biogen and Eisai’s recent lecanemab data breathed new life into the anti-amyloid approach, experts say combination therapies will likely play a significant role in treating Alzheimer’s disease.

October 6, 2022
·
6 min read
·
Alex Keown
Drug Development

TauRx Deems Phase III Data Sufficient to Send Tau Inhibitor to Regulators

TauRx announced preliminary results from the Phase III study, showing HMTM, its potent inhibitor of tau aggregates, could slow Alzheimer’s disease progression or cognitive decline.

October 6, 2022
·
3 min read
·
Tristan Manalac
FDA

Boston Cell Standards Wins First-Ever FDA 510(k) Clearance for Anatomic Pathology Controls

FDA clearance introduces first immunohistochemistry IHControls panel for evaluating breast cancers.

October 6, 2022
·
3 min read